# BIOPLEX 2200 MMRV IgG 510(k) SUMMARY

This summary of $5 1 0 ( k )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

<table><tr><td>510(k) Number</td><td>510(k) Summary Report Date</td></tr><tr><td>K091616</td><td>March 25, 2010</td></tr></table>

# MANUFACTURER INFORMATION

<table><tr><td rowspan=1 colspan=2>Manufacturer</td></tr><tr><td rowspan=1 colspan=1>Manufacturer Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, inc.Clinical Systems Division4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(510) 724-7000</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>2915274</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc.4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator No.</td><td rowspan=1 colspan=1>9929003</td></tr><tr><td rowspan=1 colspan=2>Official Correspondent for the BioPlex 2200 MMRV IgG</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185th Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>425-881-8300</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>3022521</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185th Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent</td><td rowspan=1 colspan=1>Mr. Christopher Bentsen</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(425) 498-1709</td></tr><tr><td rowspan=1 colspan=1>Fax</td><td rowspan=1 colspan=1>(425) 498-1651</td></tr></table>

# CLASSIFICATION INFORMATION

<table><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Multiplex immunoassay for measles virus, mumps virus,rubella and varicella zoster virus</td></tr><tr><td rowspan=1 colspan=1>Common Name:</td><td rowspan=1 colspan=1>Multi-Analyte Detection System - MMRV IgG</td></tr><tr><td rowspan=1 colspan=1>Product Trade Name</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG on the BioPlex 2200 Multi-AnalyteDetection System</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class II</td></tr><tr><td rowspan=1 colspan=1>Classification Panel</td><td rowspan=1 colspan=1>Microbiology</td></tr><tr><td rowspan=1 colspan=1>Regulation Number</td><td rowspan=1 colspan=1>866.3520</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>OPL</td></tr></table>

LEGALLY MARKETED EQUIVALENT (SE) DEVICES   

<table><tr><td rowspan=1 colspan=1>Comparative FDA ClearedPREDICATE DEVICE</td><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>DecisionDate</td></tr><tr><td rowspan=1 colspan=1>BioMerieux VIDAS Measles IgG (MSG)</td><td rowspan=1 colspan=1>510(k) Exempt</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>BioMerieux VIDAS Mumps IgG (MPG)</td><td rowspan=1 colspan=1>510(k) Exempt</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Bio-Rad Rubella IgG EIA</td><td rowspan=1 colspan=1>K961053</td><td rowspan=1 colspan=1>9/14/1996</td></tr><tr><td rowspan=1 colspan=1>BioMerieux VIDAS Varicella-Zoster IgG (VZV)</td><td rowspan=1 colspan=1>k923122</td><td rowspan=1 colspan=1>10/26/1992</td></tr></table>

# DEVICE DESCRIPTION

The BioPlex 2200 MMRV IgG kit uses multiplex flow immunoassay, a methodology that greatly resembles traditional ElA, but permits simultaneous detection and identification of many antibodies in a single tube. Four (4) different populations of dyed beads are coated with antigens to identiy the presence of IgG class antibodies associated with Measles, Mumps, Rubella and Varicella-zoster. The BioPlex 2200 System combines an aliquot of patient sample, sample diluent, and bead set reagent into a reaction vessel. The mixture is incubated at $\mathfrak { 3 7 ^ { \circ } C }$ After a wash cycle, anti-human IgG antibody, conjugated to phycoerythrin (PE), is added to the dyed beads and this mixture is incubated at ${ } ^ { 3 7 ^ { \circ } \mathsf { C } }$ . The excess conjugate is removed in another wash cycle, and the beads are resuspended in wash buffer. The bead mixture then passes through the detector.

The identity of the dyed beads is determined by the fluorescence of the dyes, and the amount of antibody captured by the antigen is determined by the fluorescence of the attached PE. Raw data is calculated in relative fluorescence intensity (RFl). Three additional dyed beads, an Internal Standard Bead (ISB), a Serum Verification Bead (SVB) and a Reagent Blank Bead (RBB) are present in each reaction mixture to verify detector response, the addition of serum to the reaction vessel and the absence of significant non-specific binding in serum.

Bio-Rad Laboratories.

# KIT COMPONENTS

BioPlex 2200 MMRV IgG Reagent Pack ( 665-2450). The reagent pack contains supplies sufficient for 100 tests.

<table><tr><td rowspan=1 colspan=1>Vial</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>Bead Set</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing dyed beads coated with Measles (Rubeola),Mumps, Rubella, and VZV antigens plus an Internal Standard bead (ISB), aSerum Verification bead (SVB), and a Reagent Blank bead (RBB) in bufferwith Glycerol and protein stabilizers (bovine). ProClin ™ 300 (0.3%), sodiumbenzoate (0.1%) and sodium azide (&lt; 0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>One (1) 5 mL vial, containing phycoerythrin conjugated murine monoclonalanti-human IgG antibody and phycoerythrin conjugated murine monoclonalanti-human FXIll antibody, in buffer with protein stabilizers (bovine).ProClin ™m 300 (0.3%), sodium benzoate (0.1%) and sodium azide (&lt; 0.1%)as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Sample Diluent</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing buffer with protein stabilizers (bovine andmurine). ProClin ™m 300 (0.3%), sodium benzoate (0.1%) and sodium azide(&lt; 0.1%) as preservatives.</td></tr></table>

ADDITIONAL REQUIRED ITEMS, AVAILABLE FROM BIO-RAD   

<table><tr><td rowspan=1 colspan=1>Catalog #</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>663-2400</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Calibrator Set: Three (3) 0.5 mL vials, eachcontaining human IgG antibodies to Measles, Mumps, Rubella, and VZV, ina human serum matrix made from defibrinated plasma. All antibodies arederived from human disease state plasma. All calibrators contain ProClin ™300 (0.3%), sodium benzoate (0.1%) and sodium azide (&lt; 0.1%) aspreservatives</td></tr><tr><td rowspan=1 colspan=1>663-2430</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Control Set: Two (2) 1.5 mL Positive Controlserum vials, each containing human IgG antibodies to Measles, Mumps,Rubella, and VZV, in a human serum matrix made from defibrinatedplasma; and two (2) 1.5 mL Negative Control serum vials, in a humanserum matrix made from defibrinated plasma. All antibodies are derivedfrom human disease state plasma. All controls contain ProClin ™ 300(0.3%), sodium benzoate (0.1%) and sodium azide (&lt; 0.1%) aspreservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0817</td><td rowspan=1 colspan=1>BioPlex 2200 System Sheath Fluid: Two (2) 4 L bottles containingPhosphate Buffered Saline (PBS). ProClin® 300 (0.3%) and Sodium azide(0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0818</td><td rowspan=1 colspan=1>BioPlex 2200 System Wash Solution: One (1) 10 L bottle containingPhosphate Buffered Saline (PBS) and Tween 20. ProClin® 300 (0.3%) andSodium azide (0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0000</td><td rowspan=1 colspan=1>BioPlex 2200 Instrument and Software.</td></tr></table>

# INTENDED USE / INDICATIONS FOR USE

The BioPlex™ 2200 MMRV IgG kit is a multiplex flow immunoassay intended for the qualitative detection of IgG antibodies to Measles, Mumps, Rubella, and Varicella-zoster virus (VZV) in human serum and EDTA or heparinized plasma. The BioPlex 2200 MMRV IgG kit is intended for use with the Bio-Rad BioPlex 2200 System.

This kit is intended as an aid in the determination of serological status to Measles, Mumps, Rubella, and VZV. This kit is not intended for use in screening blood or plasma donors.

The performance of this assay has not been established for use in neonates, pediatrics and immunocompromised patients, or for use at point of care facilities.

# TECHNOLOGICAL CHARACTERISTICS

The following tables summarize similarities and differences between the BioPlex 2200 MMRV IgG and the predicate Measles IgG, Mumps IgG, Rubella IgG, and VZV IgG devices used in comparative studies with the BioPlex 2200 MMRV IgG Kit.

# A. Measles IgG

Table: Similarities between reagents and materials - Measles   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Measles IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Sample Diluent, Wash Buffer</td><td rowspan=1 colspan=1>Sample Diluent, Wash.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and Multi-Analyte Positive Control.</td><td rowspan=1 colspan=1>Negative Control and PositiveControl.</td></tr></table>

Table: Similarities between reagents with regard to function and use - Measles   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Measles IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Measles.</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Measles.</td></tr></table>

Table: Differences between reagents and materials - Measles   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Measles IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads.</td><td rowspan=1 colspan=1>60 - antigen coated Solid PhaseReceptacle</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG / Phycoerythrin.</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG conjugated to alkalinephosphatase,fluorescent substrate, andblock/pre-wash</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspendthe bead reagent and introduce itinto the detector.</td><td rowspan=1 colspan=1>Not similar; not utilized by thisassay.</td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>Standard.</td></tr></table>

Table: Differences between reagents with regard to function and use - Measles   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Measles IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative multi-analyte detectionof human IgG antibodies toMeasles, Mumps, Rubella, andVaricella Zoster Virus.</td><td rowspan=1 colspan=1>Qualitative detection of humanIgG antibodies to Measles.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum, EDTA, or HeparinizedPlasma.</td><td rowspan=1 colspan=1>Serum.</td></tr></table>

# BIO RAD

# B. Mumps IgG

Table: Similarities between reagents and materials - Mumps   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Mumps IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Sample Diluent, Wash Buffer.</td><td rowspan=1 colspan=1>Sample Diluent, Wash.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and Multi-Analyte Positive Control.</td><td rowspan=1 colspan=1>Negative Control and PositiveControl.</td></tr></table>

Table: Similarities between reagents with regard to function and use - Mumps   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Mumps IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Mumps.</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Mumps.</td></tr></table>

Table: Differences between reagents and materials - Mumps   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Mumps IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads.</td><td rowspan=1 colspan=1>60 - antigen coated Solid PhaseReceptacle</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG / Phycoerythrin.</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG conjugated to alkalinephosphatase,fluorescent substrate, andblock/pre-wash</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspendthe bead reagent and introduce itinto the detector.</td><td rowspan=1 colspan=1>Not similar; not utilized by thisassay.</td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>Standard.</td></tr></table>

Table: Differences between reagents with regard to function and use - Mumps   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Mumps IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative multi-analyte detectionof human IgG antibodies toMeasles, Mumps, Rubella, andVaricella Zoster Virus.</td><td rowspan=1 colspan=1>Qualitative detection of humanIgG antibodies to Mumps.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum, EDTA, or HeparinizedPlasma.</td><td rowspan=1 colspan=1>Serum.</td></tr></table>

# C. Rubella IgG

Table: Similarities between reagents and materials - Rubella   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Rubella IgG EIA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Sample Diluent, Wash Buffer.</td><td rowspan=1 colspan=1>Sample Diluent, WashConcentrate.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and multi-analyte Positive Control.</td><td rowspan=1 colspan=1>Negative Control, Low PositiveControl, High Positive Control.</td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>Calibrators.</td></tr></table>

Table: Similarities between reagents with regard to function and use - Rubella   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Rubella IgG EIA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Rubella.</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to Rubella.</td></tr></table>

Table: Differences between reagents and materials - Rubella   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Rubella IgG EIA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads.</td><td rowspan=1 colspan=1>96 well microplate - antigencoated microwells.</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG / Phycoerythrin.</td><td rowspan=1 colspan=1>Conjugate: goat anti-human IgG,Substrate, Stop Reagent.</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspendthe bead reagent and introduce itinto the detector.</td><td rowspan=1 colspan=1>Not similar; not utilized in EIA&#x27;s.</td></tr></table>

Table: Differences between reagents with regard to function and use - Rubella   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate Rubella IgG EIA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative, multi-analytedetection of human IgGantibodies to Measles, Mumps,Rubella, and Varicella ZosterVirus.</td><td rowspan=1 colspan=1>Qualitative, semi-quantitative,and quantitative detection of IgGantibodies to Rubella.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum, EDTA, or HeparinizedPlasma.</td><td rowspan=1 colspan=1>Serum.</td></tr></table>

# D. VZV IgG

Table: Similarities between reagents and materials - VZV   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate VZV IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Sample Diluent, Wash Buffer.</td><td rowspan=1 colspan=1>Sample Diluent, Wash.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and Multi-Analyte Positive Control.</td><td rowspan=1 colspan=1>Negative Control and PositiveControl.</td></tr></table>

Table: Similarities between reagents with regard to function and use - VZV   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate VZV IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to VZV.</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to VZV.</td></tr></table>

Table: Differences between reagents and materials - VZV   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate VZV IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads.</td><td rowspan=1 colspan=1>60 - antigen coated Solid PhaseReceptacle</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG/ Phycoerythrin.</td><td rowspan=1 colspan=1>Conjugate: murine anti-humanIgG conjugated to alkalinephosphatase,fluorescent substrate, andblock/pre-wash</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspendthe bead reagent and introduce itinto the detector.</td><td rowspan=1 colspan=1>Not similar; not utilized by thisassay.</td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>Standard.</td></tr></table>

Table: Differences between reagents with regard to function and use - VZV   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 MMRV IgG Kit</td><td rowspan=1 colspan=1>Predicate VZV IgG ELFA</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative multi-analyte detectionof human IgG antibodies toMeasles, Mumps, Rubella, andVaricella Zoster Virus.            •</td><td rowspan=1 colspan=1>Qualitative detection of humanIgG antibodies to VZV.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum, EDTA, or HeparinizedPlasma.</td><td rowspan=1 colspan=1>Serum.</td></tr></table>

# PERFORMANCE SUMMARY

# A. Expected Values

The prevalence and expected values for each of the MMRV IgG assays were determined in a prospective study using serum samples from pregnant women $( N = 3 9 6 )$ ; and serum samples with a Measles, Mumps, Rubella, or VZV IgG test ordered for routine testing. The routine testing population included samples from pre-employment screening $( N = 3 9 3 )$ and samples from subjects with a Measles test ordered $( N = 1 9 7 )$ , Mumps test ordered $( N = 1 9 9 )$ , Rubella test ordered $( N = 1 9 9 )$ , or VZV Test ordered $( N = 1 9 5 )$ . Results are shown in the tables below.

Table: Pregnant Women   

<table><tr><td rowspan=1 colspan=1>Resuft</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Pos (%6)</td><td rowspan=1 colspan=1>Eqv (%)</td><td rowspan=1 colspan=1>Neg (%)</td></tr><tr><td rowspan=3 colspan=1>Measles IgG</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>14- 20</td><td rowspan=1 colspan=1>56 (94.9%)</td><td rowspan=1 colspan=1>1 (1.7%)</td><td rowspan=1 colspan=1>2 (3.4%)</td></tr><tr><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>21 - 47</td><td rowspan=1 colspan=1>305 (90.8%)</td><td rowspan=1 colspan=1>8 (2.4%)</td><td rowspan=1 colspan=1>23 (6.8%)</td></tr><tr><td rowspan=1 colspan=1>396</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>362 (91.4%)</td><td rowspan=1 colspan=1>9 (2.3%)</td><td rowspan=1 colspan=1>25 (6.3%)</td></tr><tr><td rowspan=3 colspan=1>Mumps IgG</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>14 - 20</td><td rowspan=1 colspan=1>54 (91.5%)</td><td rowspan=1 colspan=1>1 (1.7%)</td><td rowspan=1 colspan=1>4 (6.8%)</td></tr><tr><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>21 - 47</td><td rowspan=1 colspan=1>295 (87.8%)</td><td rowspan=1 colspan=1>10 (3.0%)</td><td rowspan=1 colspan=1>31 (9.2%)</td></tr><tr><td rowspan=1 colspan=1>396</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>349 (88.1%)</td><td rowspan=1 colspan=1>11 (2.8%)</td><td rowspan=1 colspan=1>36 (9.1%)</td></tr><tr><td rowspan=3 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>14 - 20</td><td rowspan=1 colspan=1>57 (96.6%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1>2 (3.4%)</td></tr><tr><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>21 - 47</td><td rowspan=1 colspan=1>314 (93.5%)</td><td rowspan=1 colspan=1>8 (2.4%)</td><td rowspan=1 colspan=1>14 (4.2%)</td></tr><tr><td rowspan=1 colspan=1>396</td><td rowspan=1 colspan=1>Total*</td><td rowspan=1 colspan=1>372 (93.9%)</td><td rowspan=1 colspan=1>8 (2.0%)</td><td rowspan=1 colspan=1>16 (4.0%)</td></tr><tr><td rowspan=3 colspan=1>VZV IgG</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>14 - 20</td><td rowspan=1 colspan=1>51 (86.4%)</td><td rowspan=1 colspan=1>1 (1.7%)</td><td rowspan=1 colspan=1>7 (11.9%)</td></tr><tr><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>21 - 47</td><td rowspan=1 colspan=1>296 (88.1%)</td><td rowspan=1 colspan=1>7 (2.1%)</td><td rowspan=1 colspan=1>33 (9.8%)</td></tr><tr><td rowspan=1 colspan=1>396</td><td rowspan=1 colspan=1>Total*</td><td rowspan=1 colspan=1>348 (87.9%)</td><td rowspan=1 colspan=1>8 (2.0%)</td><td rowspan=1 colspan=1>40 (10.1%)</td></tr></table>

\*The total includes one sample from a subject of unknown age. Note: Due to rounding, numbers across columns may not total $100 \%$ .

Table: Measles, Mumps, Rubella, or VZV Test Ordered   

<table><tr><td rowspan=1 colspan=1>Resuft</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Pos (9%6)</td><td rowspan=1 colspan=1>Eqv (%)</td><td rowspan=1 colspan=1>Neg (%)</td><td rowspan=1 colspan=1>Totad N</td></tr><tr><td rowspan=5 colspan=1>Measles IgG</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>8-20</td><td rowspan=1 colspan=1>14 (87.5%)</td><td rowspan=1 colspan=1>1 (6.3%)</td><td rowspan=1 colspan=1>1 (6.3%)</td><td rowspan=5 colspan=1>590</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>8-20</td><td rowspan=1 colspan=1>11 (78.6%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1>3 (21.4%)</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>232</td><td rowspan=1 colspan=1>21 - 87</td><td rowspan=1 colspan=1>209 (90.1%)</td><td rowspan=1 colspan=1>3 (1.3%)</td><td rowspan=1 colspan=1>20 (8.6%)</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>328</td><td rowspan=1 colspan=1>21 - 87</td><td rowspan=1 colspan=1>297 (90.5%)</td><td rowspan=1 colspan=1>12 (3.7%)</td><td rowspan=1 colspan=1>19 (5.8%)</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>531 (90.0%)</td><td rowspan=1 colspan=1>16 (2.7%)</td><td rowspan=1 colspan=1>43 (7.3%)</td></tr><tr><td rowspan=5 colspan=1>Mumps IgG</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8 - 20</td><td rowspan=1 colspan=1>17 (89.5%)</td><td rowspan=1 colspan=1>2 (10.5%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=5 colspan=1>592</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>8 - 20</td><td rowspan=1 colspan=1>16 (88.9%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1>2 (11.1%)</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>21 - 87</td><td rowspan=1 colspan=1>239 (88.5%)</td><td rowspan=1 colspan=1>9 (3.3%)</td><td rowspan=1 colspan=1>22 (8.1%)</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>285</td><td rowspan=1 colspan=1>21- 87</td><td rowspan=1 colspan=1>252 (88.4%)</td><td rowspan=1 colspan=1>11 (3.9%)</td><td rowspan=1 colspan=1>22 (7.7%)</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>524 (88.5%)</td><td rowspan=1 colspan=1>22 (3.7%)</td><td rowspan=1 colspan=1>46 (7.8%)</td></tr><tr><td rowspan=5 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>8-20</td><td rowspan=1 colspan=1>22 (81.5%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1>5 (18.5%)</td><td rowspan=5 colspan=1>592</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>8 - 20</td><td rowspan=1 colspan=1>8 (72.7%)</td><td rowspan=1 colspan=1>2 (18.2%)</td><td rowspan=1 colspan=1>1 (9.1%)</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>311</td><td rowspan=1 colspan=1>21 - 87</td><td rowspan=1 colspan=1>278 (89.4%)</td><td rowspan=1 colspan=1>8 (2.6%)</td><td rowspan=1 colspan=1>25 (8.0%)</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>21-87</td><td rowspan=1 colspan=1>210 (86.4%)</td><td rowspan=1 colspan=1>10 (4.1%)</td><td rowspan=1 colspan=1>23 (9.5%)</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>518 (87.5%)</td><td rowspan=1 colspan=1>20 (3.4%)</td><td rowspan=1 colspan=1>54 (9.1%)</td></tr><tr><td rowspan=5 colspan=1>VZV IgG</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>8-20</td><td rowspan=1 colspan=1>14 (77.8%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1>4 (22.2%)</td><td rowspan=5 colspan=1>588</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8 -20</td><td rowspan=1 colspan=1>13 (68.4%)</td><td rowspan=1 colspan=1>0 (0.0%)</td><td rowspan=1 colspan=1>6 (31.6%)</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>254</td><td rowspan=1 colspan=1>21 - 87</td><td rowspan=1 colspan=1>229 (90.2%)</td><td rowspan=1 colspan=1>5 (2.0%)</td><td rowspan=1 colspan=1>20 (7.9%)</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>297</td><td rowspan=1 colspan=1>21 - 87</td><td rowspan=1 colspan=1>270 (90.9%)</td><td rowspan=1 colspan=1>7 (2.4%)</td><td rowspan=1 colspan=1>20 (6.7%)</td></tr><tr><td rowspan=1 colspan=3>Total</td><td rowspan=1 colspan=1>526 (89.5%)</td><td rowspan=1 colspan=1>12 (2.0%)</td><td rowspan=1 colspan=1>50 (8.5%)</td></tr></table>

Note: Due to rounding numbers across columns may not total $100 \%$

# B. Reproducibility Studies

To assess reproducibility of each of the assays in the BioPlex 2200 MMRV IgG kit, a   
reproducibility panel was prepared at Bio-Rad Laboratories. The positive panel members were prepared by combining one or more antibody positive patient samples in 3 different matrices (serum, EDTA plasma, and sodium heparin plasma) with one or more of the 4 analytes contained in the BioPlex 2200 MMRV IgG (Measles, Mumps, Rubella, and VZV). The panel contained members with varying levels of antibodies to the analytes in the BioPlex 2200 MMRV IgG kit, and a positive control (antibody positive for al analytes). Reproducibility testing was performed at 3 U.S. clinical trial sites. Three lots of BioPlex 2200 MMRV IgG Reagent Packs, 3 lots of BioPlex 2200 MMRV IgG Calibrator Set and 3 lots of BioPlex 2200 MMRV IgG Control Set were used to evaluate reproducibility. Each site evaluated 1 lot of the BioPlex 2200 MMRV IgG kit. Each of the panel members and a positive and negative control was tested in quadruplicate on 1 run per day over 5 days at each of 3 sites (4 replicates x 1 run x 5 days $= 2 0$ replicates per panel member per site $\mathtt { \Omega } = 6 0$   
reproducibility according to the Clinical and Laboratory Standards Institute (CLSl) guidance EP15-A2 (Vol. 25, No. 17). The mean Antibody Index (AI), standard deviation (SD), and percent coefficient of variation $( \% C V )$ for each panel member were calculated. Serum results are shown in the tables below.

Table: Reproducibility: BioPlex 2200 Measles IgG Serum   

<table><tr><td rowspan=2 colspan=1>Measles IgGPanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMean(A)</td><td rowspan=1 colspan=2>Witthin-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.138</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.1851</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.256</td><td rowspan=1 colspan=1>10.2</td></tr><tr><td rowspan=1 colspan=1>High Posittive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.126</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.250</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>0.292</td><td rowspan=1 colspan=1>13.9</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.212</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>0.233</td><td rowspan=1 colspan=1>16.0</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.186</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>0.241</td><td rowspan=1 colspan=1>13.5</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.087</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.131</td><td rowspan=1 colspan=1>14.8</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.093</td><td rowspan=1 colspan=1>10.4</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.091</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.119</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.332</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>0.364</td><td rowspan=1 colspan=1>12.3</td></tr></table>

\* Between site includes between lot variance.

Table: Reproducibility: BioPlex 2200 Mumps IgG Serum   

<table><tr><td rowspan=2 colspan=1>Mumps lgGPane! Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMean(AI)</td><td rowspan=1 colspan=2>Within-Rum</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-SIite*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%6CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.160</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.196</td><td rowspan=1 colspan=1>7.2</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.108</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.104</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.283</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.321</td><td rowspan=1 colspan=1>10.2</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.119</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>4.7.</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.169</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.193</td><td rowspan=1 colspan=1>7.5</td></tr></table>

\* Between site includes between lot variance.

Table: Reproducibility: BioPlex 2200 Rubella IgG Serum   

<table><tr><td rowspan=2 colspan=1>Rubella Ig6Panel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMean(AI)</td><td rowspan=1 colspan=2>Withtn-Rum</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.163</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>0.190</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.403</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>0.421</td><td rowspan=1 colspan=1>15.2</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.068</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>8.0</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.167</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>0.211</td><td rowspan=1 colspan=1>12.1</td></tr><tr><td rowspan=1 colspan=1>Near Curtoff 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>11.0</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>10.9</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.068</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>0.191</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>0.225</td><td rowspan=1 colspan=1>10.7</td></tr></table>

\*Between site variance includes between lot variance.

# BIO RAD

Table: Reproducibility: BioPlex 2200 VZV IgG Serum   

<table><tr><td rowspan=2 colspan=1>VZV IgGPanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMean(A)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.238</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.254</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.103</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.323</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>0.349</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>9.3</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>9.8</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>High Negative 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=1>High Negative 2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>13.6</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.174</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0.194</td><td rowspan=1 colspan=1>7.9</td></tr></table>

\* Between site includes between lot variance.

# C. Comparative Testing

# Comparative Testing: Prospective

Performance of the MMRV IgG kit was evaluated against corresponding commercially available Measles, Mumps, Rubella, and VZV immunoassays. Serum samples from pregnant women $( \mathsf { N } =$ EPY 396) and serum samples with a Measles, Mumps, Rubella, or VZV IgG test ordered $( N = 1 1 8 3 )$ were tested at 3 U.S. clinical trial sites. Serum samples with a Measles, Mumps, Rubella, or VZV IgG test ordered included serum samples submitted for routine testing $( \mathsf { N } = 7 9 0 )$ and serum samples for pre-employment evaluation $( N = 3 9 3 )$ . Results for all populations are shown in the tables below. Equivocal results obtained for Mumps and Measles on the commercially available ElAs were further tested on two additional commercially available ElAs for consensus. The consensus results are presented in the tables for Mumps and Measles, below. Equivocal results obtained for Rubella on the commercially available ElA were re-tested on the commercially available ElA, following the manufacturer's recommendations. Re-test results are presented in the tables for Rubella, below.

# BIO RAD

Table: Pregnant Women: BioPlex 2200 MMRV IgG vs. EIA $( N = 3 9 6 )$ E   

<table><tr><td rowspan=2 colspan=3>Pregnant Women</td><td rowspan=1 colspan=6>BloPlex 2200 MMAV IgG</td></tr><tr><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Pos (+)% Agreement</td><td rowspan=1 colspan=1>Neg (-)% Agreement</td></tr><tr><td rowspan=16 colspan=1>C ee eM</td><td rowspan=4 colspan=1>90 seseas</td><td rowspan=1 colspan=1>POs (+)</td><td rowspan=1 colspan=1>362</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>380</td><td rowspan=4 colspan=1>93.3%(362/388)95% CI90.4 - 95.4%</td><td rowspan=4 colspan=1>100%(8/8)95% CI67.5 - 100%</td></tr><tr><td rowspan=1 colspan=1>Eqv*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>362</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>396</td></tr><tr><td rowspan=4 colspan=1>gb sdung</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>349</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>370</td><td rowspan=4 colspan=1>94.3%(349/370)95% 91.5 - 96.3%</td><td rowspan=4 colspan=1>96.2%(25/26)95% CI81.1 - 99.3%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Totad</td><td rowspan=1 colspan=1>349</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>396</td></tr><tr><td rowspan=4 colspan=1>gh elpag</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>369</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>377</td><td rowspan=4 colspan=1>97.9%(369/377)95% Cl95.9 - 98.9%</td><td rowspan=4 colspan=1>73.7%(14/19)95% CI51.2 - 88.2%</td></tr><tr><td rowspan=1 colspan=1>Eqv*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>372</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>396</td></tr><tr><td rowspan=4 colspan=1>90IAZA</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>348</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>360</td><td rowspan=4 colspan=1>95.1%(348/366)95% Cl92.4 - 96.9%</td><td rowspan=4 colspan=1>100%(30/30)95% CI88.6 - 100%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>348</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>396</td></tr></table>

\* Results obtained by a consensus of two out of three commercially available EIAs. \*\*Result after re-testing with the commercially available ElA following the manufacturer's recommendations.

Table: Test Ordered Samples: BioPlex 2200 MMRV IgG vs. EIA $( N = 1 1 8 3 )$   

<table><tr><td rowspan=2 colspan=3>Meastes, Mumps,Rubella, or VZV TestOrdered</td><td rowspan=1 colspan=6>BloPlex 2200 MMRV IgG</td></tr><tr><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Pos (+)% Agreement</td><td rowspan=1 colspan=1>Neg (-)% Agreement</td></tr><tr><td rowspan=16 colspan=1>CO e Ce</td><td rowspan=4 colspan=1>M sesec</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>1042</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>1093</td><td rowspan=4 colspan=1>94.7%(1042/1100)95% CI93.2 - 95.9%</td><td rowspan=4 colspan=1>80.2%  (65/81)95% C70.3 - 87.5%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>79</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1048</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>1183</td></tr><tr><td rowspan=4 colspan=1>9bsum</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>1006</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>1106</td><td rowspan=4 colspan=1>90.4%(1006/1113)95% CI88.5 - 92.0%</td><td rowspan=4 colspan=1>91.0%(61/67)95% Cl81.8 - 95.8%</td></tr><tr><td rowspan=1 colspan=1>Eqv*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1007</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>1183</td></tr><tr><td rowspan=4 colspan=1>Hh eyee</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>1060</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>1117</td><td rowspan=4 colspan=1>94.8%(1060/1118)95% CI93.3 - 96.0%</td><td rowspan=4 colspan=1>86.2%(56/65)95% Cl75.7 - 92.5%</td></tr><tr><td rowspan=1 colspan=1>Eqv*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1064</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>1183</td></tr><tr><td rowspan=4 colspan=1>9OI AZA</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>1047</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1099</td><td rowspan=4 colspan=1>94.0%(1047/1114)95% CI92.4 - 95.2%</td><td rowspan=4 colspan=1>98.4%(60/61)95% C91.3 - 99.7%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1048</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>1183</td></tr></table>

\* Results obtained by a consensus of two out of three commercially available ElAs. \*Result after re-testing with the commercially available ElA following the manufacturer's recommendations.

# Comparative Testing: Retrospective

Performance of the MMRV IgG kit was evaluated against corresponding commercially available Measles, Mumps, Rubella, and VZV immunoassays using retrospective serum samples negative for antibodies to Measles $( N = 9 3 )$ , Mumps $( N = 9 5 )$ , Rubella $( N = 2 6 8 )$ , or VZV $( N = 1 4 3 )$ .The negative samples for Measles and Mumps were selected using a consensus of two out of three commercially available EIAs. Negative samples for Rubella and VZV were selected using the respective commercially available ElAs used for the comparative analysis. Results are shown in the table below.

Table: Retrospective Negative Samples: BioPlex 2200 MMRV IgG vs. EIA   

<table><tr><td rowspan=2 colspan=3>RetrospectiveMeasies, Mumps,Rubella, or VZVNegative Samples</td><td rowspan=1 colspan=5>BioPlex 2200 MMAV IgG</td></tr><tr><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Neg (-)% Agreement</td></tr><tr><td rowspan=16 colspan=1>C e e Ae </td><td rowspan=4 colspan=1>Ms0g(E6 = N)</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=4 colspan=1>100%(93/93)95% Cl96.0 - 100%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>93</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>93</td></tr><tr><td rowspan=4 colspan=1>gBi sdwnw(96 = 1)</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=4 colspan=1>100%(83/83)95% Cl95.6 - 100%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>83</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=8 colspan=1>R(89Z = N)901 AZA(EVL = N)</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=4 colspan=1>95.9%(257/268)95% Cl92.8 - 97.7%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>257</td><td rowspan=1 colspan=1>268</td></tr><tr><td rowspan=2 colspan=1>TotalPos (+)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>257</td><td rowspan=1 colspan=1>268</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=4 colspan=1>100%(143/143)95% CI97.4 - 100%</td></tr><tr><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>143</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>143</td></tr></table>

# Correlation with CDC Rubella Evaluation Serum Panel

The performance of the BioPlex 2200 MMRV IgG kit was assessed using a masked, characterized Rubella IgG serum panel from the CDC. The panel consisted of 82 positive samples and 18 negative samples. The results are presented as a means to convey further information on the performance of the test kit and do not imply endorsement of the assay by the CDC. Results are shown in the table below.

Table: Characteristics of CDC Rubella IgG Reference Sera $( \mathsf { N } = \mathsf { 1 0 0 } )$   

<table><tr><td rowspan=1 colspan=1>CDC Samples</td><td rowspan=1 colspan=1>Reference Result</td><td rowspan=1 colspan=1>BioPlex 2200 Pos (+)</td><td rowspan=1 colspan=1>BioPlex 2200 Neg (-)</td></tr><tr><td rowspan=2 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>1*</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td></tr></table>

in other member of this pair tested positive.

# Correlation of the BioPlex 2200 MMRV IgG Rubella IgG Assay with the WHO Standard

Dilutions of the WHO anti-Rubella immunoglobulin, 1st International Standard, RUBl-1-94, in the range of $0 . 2 0 1 \downarrow 1 / m \vert$ , were analyzed with the BioPlex 2200 Rubella IgG assay. Results can be found in the table below.

Table: Rubella World Health Organization RUBI-1-94 Sample Evaluation   

<table><tr><td rowspan=2 colspan=1>Expected (U/ml</td><td rowspan=1 colspan=2>BloPlex 2200</td></tr><tr><td rowspan=1 colspan=1>Measured Mean AI (1.0 Al= 10 (U/ml)</td><td rowspan=1 colspan=1>Mean Percent of Expected</td></tr><tr><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>121</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>82</td></tr><tr><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>80</td></tr></table>

# CDC Rubella Low Positive Control Testing

A lyophilized CDC low positive control serum was prepared by and tested at ne clinical trial site. The control was tested neat and diluted $1 / 2$ i plRu shown in the table below.

Table: Mean Low-Titer Anti-Rubella Human Reference Serum CDC Biological Standard Results $( N = 2 )$ EPY   

<table><tr><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Mean(AI)</td></tr><tr><td rowspan=1 colspan=1>Neat - Prepared per package insert</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>1/2 Dilution</td><td rowspan=1 colspan=1>1.4</td></tr></table>

# D. Cross-Reactivity

A cross-reactivity study was performed to determine if samples from various disease states and other potentially cross-reacting agents interfere with test results when tested with the BioPlex 2200 MMRV IgG kit. Samples known to be positive for one of the thirteen potential crossreactants listed in the table below were evaluated with the BioPlex 2200 MMRV IgG assays. Due to the high prevalence of IgG antibodies to Measles, Mumps, Rubella, and VZV in the population, and in order to properly evaluate the potential cross-reactivity, all samples were pre-tested by commercially available Measles, Mumps, Rubella and VZV assays and only those that tested negative by the commercially available assay were further tested by the BioPlex 2200 MMRV IgG kit. The table below summarizes negative agreement between the BioPlex 2200 MMRV IgG assays and the corresponding commercially available Measles, Mumps, Rubella and VZV assays within each of the thirteen cross-reactant panels. The results demonstrate that the various disease state samples evaluated do not cross-react with the 4 antigens in the BioPlex 2200 MMRV IgG kit. Please note that for HCV Ab and ANA IgG, potential cross-reactivity was not well assessed due to the limitation of the sample size tested.

Table: Cross-Reactivity   

<table><tr><td rowspan=3 colspan=1>PotentialCross-Reactant</td><td rowspan=1 colspan=8>Number of Negative BioPlex 2200 Resutts 7Number of Negative Commercially Avallabte Assay Resufts</td></tr><tr><td rowspan=1 colspan=2>Measles</td><td rowspan=1 colspan=2>Mumps</td><td rowspan=1 colspan=2>Rubella</td><td rowspan=1 colspan=2>Vzv</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>NegativeAgreement</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>NegativeAgreement</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>NegativeAgreement</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>NegativeAgreement</td></tr><tr><td rowspan=1 colspan=1>ANA IgG</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5/5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5/5</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>2/2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5/5</td></tr><tr><td rowspan=1 colspan=1>CMV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>EBV VCA IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>HBsAb IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>HCV Ab</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>1/1</td></tr><tr><td rowspan=1 colspan=1>HSV-1 IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>HSV-2 lgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Measles IgG</td><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Mumps IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Parvovirus B19 IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Toxoplasma IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6/6</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>VZV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N/A</td></tr></table>

\* Potential cross-reactivity was not well assessed due to the limitation of the sample size tested.

Bio-Rad Laboratories, Inc.   
c/o Mr. David Bhend   
Regulatory Affairs Representative   
Bio-Rad Laboratories - Redmond Operations 6565 185th Ave NE   
Redmond, WA 98052

Re: K091616 Trade/Device Name: BioPlex 2200 MMRV IgG on the BioPlex 2200 Multi-Analyte Detection System Regulation Number: 21 CFR§ 866.3510 Regulation Name: Rubella Virus Serological Reagents Regulatory Class: Class II Product Code: OPL, LJB, LJY, LFY Dated: March 25, 2010 Received: March 26, 2010.

Dear Mr. Bhend:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations adminitered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will alow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indication for Use

510(k) Number (if known): k091616

Device Name: BioPlex 2200 MMRV IgG kit on the BioPlex 2200 Multi-Analyte Detection System

Indication For Use:

The BioPlexTM 2200 MMRV IgG kit is a multiplex flow immunoassay intended for the qualitative detection of IgG antibodies to Measles, Mumps, Rubella, and Varicella-zoster virus (VZV) in human serum and EDTA or heparinized plasma. The BioPlex 2200 MMRV lgG kit is intended for use with the Bio-Rad BioPlex 2200 System.

This kit is intended as an aid in the determination of serological status to Measles, Mumps, Rubella, and VZV. This kit is not intended for use in screening blood or plasma donors.

The performance of this assay has not been established for use in neonates, pediatrics and immunocompromised patients, or for use at point of care facilities.

Prescription Use X And/Or Over the Counter Use (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/096eeb83399ff427e3396d951ddfd01e7e264c7df03f43fab3fef1c925d64965.jpg)

Division Sign-Off 1 Office of In Vitro Diagnostic Device Evaluation and Safety